NRSN News

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Announces Pricing of Insider-Led PIPE Financing

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements